Procognia plans IPO on TASE

Biotech company, Procognia-Israel, has filed to list on the Tel Aviv Stock Exchange, the company said Wednesday.

By LEAH GRANOF
December 21, 2006 06:49

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later Don't show it again

Biotech company, Procognia-Israel, has filed to list on the Tel Aviv Stock Exchange, the company said Wednesday. The company specializes in life-science technology, particularly in the development of carbohydrate analysis products that can be used for the production of biopharmaceuticals. Although it has not yet decided on the structure or scope of its offering, the company is earmarking proceeds from the expected IPO for marketing its flagship products including the GlycoScope and the Qproteome GlcycoArray. Procognia's UK-based parent company has shareholders that include APAX Partners Investment Fund, the Evergreen Venture Capital Group, Koor, Vitalife and Star Ventures Capital Funds. Procognia-Israel is based out of Ashdod and employs 25 people.

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection

By GLOBES, NIV ELIS